TELA News and Press, TELA Bio Inc. From 05/13/21

MALVERN, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported...

Image source: The Motley Fool. TELA Bio Inc. (NASDAQ: TELA) Q4 2020 Earnings Call Mar 24, 2021 , 4:30 p.m. ET Continue reading For further details see: TELA Bio Inc. (TELA) Q4 2020 Earnings Call Transcript

MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the co...

TELA Bio Inc (TELA) Q4 2020 Earnings Conference Call March 24, 2021, 04:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, IR Antony Koblish - President and CEO Nora Brennan - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Anthony Petrone - J...

TELA Bio (TELA): Q4 GAAP EPS of -$0.54 misses by $0.07.Revenue of $5.67M (+16.7% Y/Y) beats by $0.1M.Cash and cash equivalents on December 31, 2020 were $74.4 million.2021 Outlook: TELA Bio expects total revenue to be in the range of $27.0 million to $30.0 million, representing growth of...

MALVERN, Pa., March 24, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial re...

MALVERN, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the results...

MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the co...

MALVERN, Pa., Feb. 04, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Com...

TELA Bio (TELA) reports preliminary Q4 and FY 2020 results. Q4 rand FY20 revenue is expected to be $5.5M - $5.7M (consensus $6.03M) and $18.0M - 18.2M (est. $18.52M), respectively.Cash and equivalents at December 31, 2020 is expected to be $74.4M. "Our revenue in the fourth quarter conti...